美康生物(300439.SZ):便攜式尿液分析儀獲醫療器械註冊證
格隆匯3月4日丨美康生物(300439.SZ)公佈,公司全資子公司美康盛德醫療科技(蘇州)有限公司於近日取得由江蘇省藥品監督管理局頒發的便攜式尿液分析儀《中華人民共和國醫療器械註冊證》。
該儀器與京都弘益生物科技(蘇州)有限公司尿液分析試紙條配套使用,供醫療機構對人體尿液樣本中的生化成分進行半定量或定性檢測,為臨牀檢驗和診斷提供參考。可檢測項目包括:尿膽原、潛血、膽紅素、酮體、白細胞、葡萄糖、蛋白質、酸鹼度、亞硝酸鹽、比重、維生素C。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.